Disease State Information on TNBC

Panelists discuss how:
Triple-negative breast cancer (TNBC) remains one of the most aggressive and difficult-to-treat subtypes. The experts outline its molecular heterogeneity, lack of hormone receptor targets, and poor prognosis. They describe evolving molecular profiling efforts that identify actionable mutations and biomarkers. The conversation emphasizes how immunotherapy, ADCsantibody-drug conjugates, and combination regimens are reshaping standard-of-care options and improving survival outcomes for this challenging population.